Diagnosis and Initiation of Treatment in Parkinson's Disease

REFERENCES

• Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology. 2009 May 26;72(21 Suppl 4):S1–136.
   PubMedGoogle Scholar
• Adler CH. Nonmotor complications in Parkinson's disease. Mov Disord. 2005;20 Suppl 11:S23–9.
   PubMedGoogle Scholar
• Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, Poncet M, Cherif AA. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology. 2002 Aug 13;59(3):408–13.
   PubMedGoogle Scholar
• Schrag A, Ben-Shlomo Y, Quinn N. How valid is the clinical diagnosis of Parkinson's disease in the community? J Neurol Neurosurg Psychiatry. 2002 Nov;73(5):529–34.
   PubMedGoogle Scholar
• Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181–4.
   PubMed Web of Science ®Google Scholar
• Suchowersky O, Reich S, Perlmutter J, Zesiewicz T, Gronseth G, Weiner WJ. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 Apr 11;66(7):968–75.
   PubMedGoogle Scholar
• Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing. 1999 Mar;28(2):99–102.
   PubMedGoogle Scholar
• Brooks DJ. Neuroimaging in Parkinson's disease. NeuroRx. 2004 Apr;1(2):243–54.
   PubMedGoogle Scholar
• Asenbaum S, Pirker W, Angelberger P, Bencsits G, Pruckmayer M, Brucke T. [123I]beta-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm. 1998;105(10–12):1213–28.
   PubMedGoogle Scholar
• Benamer HT, Oertel WH, Patterson J, Hadley DM, Pogarell O, Hoffken H, Gerstner A, Grosset DG. Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations. Mov Disord. 2003 Sep;18(9):977–84.
   PubMedGoogle Scholar
• Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, Speelman JD, Horstink MH, Sips HJ, Dierckx RA, Versijpt J, Decoo D, Van Der Linden C, Hadley DM, Doder M, Lees AJ, Costa DC, Gacinovic S, Oertel WH, Pogarell O, Hoeffken H, Joseph K, Tatsch K, Schwarz J, Ries V. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord. 2000 May;15(3):503–10.
   PubMedGoogle Scholar
• Jennings DL, Seibyl JP, Oakes D, Eberly S, Murphy J, Marek K. (123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol. 2004 Aug;61(8):1224–9.
   PubMedGoogle Scholar
• Easterford K, Clough P, Kellett M, Fallon K, Duncan S. Reversible parkinsonism with normal beta-CIT-SPECT in patients exposed to sodium valproate. Neurology. 2004 Apr 27;62(8):1435–7.
   PubMedGoogle Scholar
• Huang CC, Yen TC, Shih TS, Chang HY, Chu NS. Dopamine transporter binding study in differentiating carbon disulfide induced parkinsonism from idiopathic parkinsonism. Neurotoxicology. 2004 Mar;25(3):341–7.
   PubMedGoogle Scholar
• Gerschlager W, Bencsits G, Pirker W, Bloem BR, Asenbaum S, Prayer D, Zijlmans JC, Hoffmann M, Brucke T. [123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease. Mov Disord. 2002 May;17(3):518–23.
   PubMedGoogle Scholar
• Tzen KY, Lu CS, Yen TC, Wey SP, Ting G. Differential diagnosis of Parkinson's disease and vascular parkinsonism by (99m)Tc-TRODAT-1. J Nucl Med. 2001 Mar;42(3):408–13.
   PubMedGoogle Scholar
• Benaderette S, Zanotti Fregonara P, Apartis E, Nguyen C, Trocello JM, Remy P, Devaux JY, Askienazy S, Vidailhet M. Psychogenic parkinsonism: a combination of clinical, electrophysiological, and [(123)I]-FP-CIT SPECT scan explorations improves diagnostic accuracy. Mov Disord. 2006 Mar;21(3):310–7.
   PubMedGoogle Scholar
• Gaig C, Marti MJ, Tolosa E, Valldeoriola F, Paredes P, Lomena FJ, Nakamae F. 123I-Ioflupane SPECT in the diagnosis of suspected psychogenic Parkinsonism. Mov Disord. 2006 Nov;21(11):1994–8.
   PubMedGoogle Scholar
• Marras C, McDermott MP, Marek K, Rochon P, Naglie G, Tanner CM, Rudolph A, Shoulson I, Lang AE. Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. Mov Disord. 2011 Mar;26(4):608–13.
   PubMedGoogle Scholar
• Lang AE. The progression of Parkinson disease: a hypothesis. Neurology. 2007 Mar 20;68(12):948–52.
   PubMedGoogle Scholar
• Schapira AH, Olanow CW. Drug selection and timing of initiation of treatment in early Parkinson's disease. Ann Neurol. 2008 Dec;64 Suppl 2:S47–55.
   PubMedGoogle Scholar
• Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2002 Jan 8;58(1):11–7.
   PubMedGoogle Scholar
• Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord. 2005 May;20(5):523–39.
   PubMedGoogle Scholar
• Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Friedman A, Kanovsky P, Larsen JP, Lees A, Oertel W, Poewe W, Rascol O, Sampaio C. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol. 2006 Nov;13(11):1170–85.
   PubMedGoogle Scholar
• National Collaborating Centre for Chronic Conditions. Parkinson's disease: national clinical guideline for diagnosis and management in primary and secondary care. London, England: Royal College of Physicians; 2006.
   Google Scholar
• Scottish Intercollegiate Guidelines Network. Diagnosis and pharmacological management of Parkinson's disease: a national clinical guideline. Edinburgh, Scotland: SIGN, 2010.
   Google Scholar
• Hirsch MA, Farley BG. Exercise and neuroplasticity in persons living with Parkinson's disease. Eur J Phys Rehabil Med. 2009 Jun;45(2):215–29.
   PubMedGoogle Scholar
• Russell JA, Ciucci MR, Connor NP, Schallert T. Targeted exercise therapy for voice and swallow in persons with Parkinson's disease. Brain Res. 2010 Jun 23;1341:3–11.
   PubMedGoogle Scholar
• Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain. 2000 Nov;123(Pt 11):2297–305.
   PubMedGoogle Scholar
• Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004 Dec 9;351(24):2498–508.
   PubMedGoogle Scholar
• Hauser RA, Auinger P, Oakes D. Levodopa response in early Parkinson's disease. Mov Disord. 2009 Dec 15;24(16):2328–36.
   PubMedGoogle Scholar
• Schrag A, Ben-Shlomo Y, Brown R, Marsden CD, Quinn N. Young-onset Parkinson's disease revisited—clinical features, natural history, and mortality. Mov Disord. 1998 Nov;13(6):885–94.
   PubMedGoogle Scholar
• Koller WC, Hutton JT, Tolosa E, Capilldeo R. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology. 1999 Sep 22;53(5):1012–9.
   PubMedGoogle Scholar
• Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease. Mov Disord. 2009 Mar 15;24(4):541–50.
   PubMed Web of Science ®Google Scholar
• Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010 Jul;68(1):18–27.
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med. 1989 Nov 16;321(20):1364–71.
   PubMedGoogle Scholar
• Palhagen S, Heinonen EH, Hagglund J, Kaugesaar T, Kontants H, Maki-Ikola O, Palm R, Turunen J. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology. 1998 Aug;51(2):520–5.
   PubMedGoogle Scholar
• Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002 Dec;59(12):1937–43.
   PubMedGoogle Scholar
• Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, Tolosa E. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009 Sep 24;361(13):1268–78.
   PubMedGoogle Scholar
• Palhagen S, Heinonen E, Hagglund J, Kaugesaar T, Maki-Ikola O, Palm R. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology. 2006 Apr 25;66(8):1200–6.
   PubMedGoogle Scholar
• Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004 Apr;61(4):561–6.
   PubMedGoogle Scholar
• Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord. 2009 Dec 11;24(4):562–71.
   Google Scholar
• Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. JAMA. 1997 Jul 9;278(2):125–30.
   PubMedGoogle Scholar
• Kieburtz K. Twice-daily, low-dose pramipexole in early Parkinson's disease: a randomized, placebo-controlled trial. Mov Disord. 2011 Jan;26(1):37–44.
   PubMedGoogle Scholar
• Hauser RA, Schapira AH, Rascol O, Barone P, Mizuno Y, Salin L, Haaksma M, Juhel N, Poewe W. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Mov Disord. 2010 Nov 15;25(15):2542–9.
   PubMedGoogle Scholar
• Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, Taylor RL, Sanchez-Ramos J, O'Brien CF. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology. 1997 Aug;49(2):393–9.
   PubMedGoogle Scholar
• Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin. 2008 Oct;24(10):2883–95.
   PubMedGoogle Scholar
• Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004 Jul;61(7):1044–53.
   PubMedGoogle Scholar
• Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med. 2000 May 18;342(20):1484–91.
   PubMedGoogle Scholar
• Watts RL, Lyons KE, Pahwa R, Sethi K, Stern M, Hauser RA, Olanow W, Gray AM, Adams B, Earl NL. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. Mov Disord. 2010 May 15;25(7):858–66.
   PubMedGoogle Scholar
• Comella CL. Sleep disorders in Parkinson's disease: an overview. Mov Disord. 2007 Sep;22 Suppl 17:S367–73.
   PubMedGoogle Scholar
• Paus S, Brecht HM, Koster J, Seeger G, Klockgether T, Wullner U. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord. 2003 Jun;18(6):659–67.
   PubMedGoogle Scholar
• Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010 May;67(5):589–95.
   PubMedGoogle Scholar
• Mamikonyan E, Siderowf AD, Duda JE, Potenza MN, Horn S, Stern MB, Weintraub D. Long-term follow-up of impulse control disorders in Parkinson's disease. Mov Disord. 2008 Jan;23(1):75–80.
   PubMedGoogle Scholar
• Lyons KE, Friedman JH, Hermanowicz N, Isaacson SH, Hauser RA, Hersh BP, Silver DE, Tetrud JW, Elmer LW, Parashos SA, Struck LK, Lew MF, Pahwa R. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects. Clin Neuropharmacol. 2010 Jan-Feb;33(1):5–10.
   PubMedGoogle Scholar
• Lyons KE, Pahwa R. Amantadine. In: Ebadi M, Pfeiffer RF, editors. Parkinson's disease. Boca Raton, FL: CRC Press; 2005. p. 685–90.
   Google Scholar
• Silver DE, Sahs AL. Double blind study using amantadine hydrochloride in the therapy of Parkinson's disease. Trans Am Neurol Assoc. 1971;96:307–8.
   PubMedGoogle Scholar